<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Golodirsen: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Golodirsen: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Golodirsen: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="126392" href="/d/html/126392.html" rel="external">see "Golodirsen: Drug information"</a> and <a class="drug drug_patient" data-topicid="126394" href="/d/html/126394.html" rel="external">see "Golodirsen: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53914808"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vyondys 53</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F53917275"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antisense Oligonucleotide</span></li></ul></div>
<div class="block dop drugH1Div" id="F53945057"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Determine serum cystatin C, urine dipstick (proteinuria), and urine protein-to-creatinine ratio prior to therapy; also consider baseline GFR using an exogenous filtration marker.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cc06b31-bbc9-4530-9118-12d395c83705">Duchenne muscular dystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Duchenne muscular dystrophy (DMD):</b> Children and Adolescents: IV: 30 mg/kg/dose once weekly. <b>Note:</b> Dosing based on clinical trials in pediatric patients aged 6 to 13 years at study entry.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity reactions: Consider slowing infusion or interrupting therapy.</p></div>
<div class="block dorp drugH1Div" id="F53945058"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Renal clearance is reduced in non-Duchenne muscular dystrophy (DMD) adult patients with renal impairment; patients with known kidney impairment should be closely monitored; however, creatinine is not a reliable measurement of kidney function due to the reduced skeletal muscle mass in patients with DMD. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be monitored; consult pediatric nephrologist if persistent increase in serum cystatin C or proteinuria develops.</p></div>
<div class="block dohp drugH1Div" id="F53945059"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F53996555"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="126392" href="/d/html/126392.html" rel="external">see "Golodirsen: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cc06b31-bbc9-4530-9118-12d395c83705">Duchenne muscular dystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Duchenne muscular dystrophy</b>
<b>:</b> IV: 30 mg/kg once weekly.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F53996557"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; monitor closely.</p></div>
<div class="block doha drugH1Div" id="F53996558"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F53937085"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (41%), falling (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (27%), vomiting (27%), nausea (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (27%), nasopharyngitis (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (41%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (&gt;5%), pain (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Excoriation of skin (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (&gt;5%), diarrhea (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Seasonal allergy (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Catheter-site reaction (&gt;5%), infusion-site pain (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (&gt;5%), bone fracture (&gt;5%), sprain (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otic infection (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oropharyngeal pain (&gt;5%), rhinitis (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis, exfoliation of skin, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F53917186"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F53996543"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including rash, pyrexia, pruritus, urticaria, dermatitis, and skin exfoliation) have been reported with use; manage appropriately and consider slowing the infusion or interrupting therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney toxicity: Kidney toxicity, including potentially fatal glomerulonephritis, has been observed with some antisense oligonucleotides. Creatinine may not be a reliable measure of kidney function in patients with Duchenne muscular dystrophy. Refer to nephrologist if persistent increases in serum cystatin C or proteinuria occur.</p></div>
<div class="block foc drugH1Div" id="F53914809"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vyondys 53: 100 mg/2 mL (2 mL)</p></div>
<div class="block geq drugH1Div" id="F53914807"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53986100"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vyondys 53 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/2 mL (per mL): $960.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F53945061"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Must be diluted prior to administration. Administer by IV infusion over 35 to 60 minutes through a 0.2-micron, low protein binding, in-line filter attached to the primary IV tubing; infusion must be completed within 4 hours of preparation. Flush IV access line with NS prior to and after infusion; may consider application of a topical anesthetic cream to the infusion site prior to administration. Do not mix with other medications or infuse other medications concomitantly via the same IV access line. If hypersensitivity reaction occurs, consider slowing the infusion or interrupting therapy. If a dose is missed, administer as soon as possible after the scheduled time.</p></div>
<div class="block adm drugH1Div" id="F53996560"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Dilution required prior to administration. Administer by IV infusion over 35 to 60 minutes immediately after dilution through a 0.2-micron, low protein-binding, in-line filter attached to the primary IV tubing; complete infusion within 4 hours (stable for 4 hours at room temperature). Use of a topical anesthetic cream on the infusion site may be considered prior to administration. Flush IV access line with NS before and after infusion. Do not mix with other medications or infuse other medications concomitantly via the same IV access line. Consider slowing the infusion or interrupting therapy for hypersensitivity reactions. Discard unused portion.</p></div>
<div class="block sts drugH1Div" id="F53996545"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze. Diluted solution may be stored for up to 24 hours at 2°C to 8°C (36°F to 46°F).</p></div>
<div class="block usep drugH1Div" id="F53917276"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping (FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Indication received accelerated approval based on an increase in skeletal muscle dystrophin production in initial trials; continued approval may be contingent upon confirmatory trials.</p></div>
<div class="block mst drugH1Div" id="F53996540"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Golodirsen may be confused with Goldenseal, Golden Seal, gold sodium thiomalate.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F53978902"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53978899"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F53996541"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies or studies in females have not been conducted.</p></div>
<div class="block mopp drugH1Div" id="F53945062"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">GFR using an exogenous filtration marker (baseline); proteinuria (baseline and monthly by urine dipstick); serum cystatin C and urine protein-to-creatinine ratio (baseline and every 3 months); urine samples should be obtained prior to infusion or at least 48 hours after the most recent infusion and use laboratory tests that do not use reagent pyrogallol red (may cross react with golodirsen leading to false positive); hypersensitivity reactions during infusion.</p></div>
<div class="block pha drugH1Div" id="F53996547"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to exon 53 of dystrophin pre-messenger RNA (mRNA), resulting in exclusion of this exon during mRNA processing. Exon 53 skipping allows for production of an internally truncated dystrophin protein in patients with genetic mutations that are amenable to exon 53 skipping.</p></div>
<div class="block phk drugH1Div" id="F53996548"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 0.67 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Plasma: 33% to 39%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 3.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (mostly unchanged).</p></div>
<div class="block phksp drugH1Div" id="F53996553"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In non-Duchenne muscular dystrophy adults with chronic kidney disease (CKD), AUC increased ~1.2-fold and 1.9-fold in stage 2 CKD and stage 3 CKD, respectively. C<sub>max</sub> increased 1.2-fold in patients with stage 3 CKD.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58846921"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Vyondys 53</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Vyondys 53</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Vyondys 53</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Revision to administration instructions for Vyondys 53 (golodirsen), Sarepta Therapeutics [data on file, July 2020].</div>
</li>
<li>
<div class="reference">
                  Vyondys 53 (golodirsen) [prescribing information]. Cambridge, MA: Sarepta Therapeutics Inc; February 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 126393 Version 32.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
